Al­lo­gene, Over­land plot speedy Asia play for off-the-shelf CAR-T with $117M joint ven­ture

David Chang got a good look at what it takes to bring CAR-T ther­a­py to Chi­na and Asia mar­kets when he and Arie Bellde­grun struck a deal with Fo­s­un Phar­ma to form a joint ven­ture around its pi­o­neer­ing lym­phoma treat­ment — which would come to be known as Yescar­ta — in 2017, just af­ter sub­mit­ting a BLA to the FDA.

With Al­lo­gene, the duo’s high pro­file start­up aimed at de­liv­er­ing off-the-shelf CAR-T, he’s do­ing the same.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER